Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Solu-Medrol

Solu-Medrol is a medicine containing the active ingredient(s) methylprednisolone. On this page you will find out more about Solu-Medrol, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: methylprednisolone

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Solu-Medrol (5 x 500 mg vials, 5 x 8 mL inert diluent vials), 1 pack

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, SOLU-MEDROL Powder for Injection is indicated only for intravenous or intramuscular use in the following conditions: 1. ENDOCRINE DISORDERS: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia; Nonsuppurative thyroiditis; Hypercalcaemia associated with cancer. 2. RHEUMATIC DISORDERS: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Ankylosing spondylitis; Psoriatic arthritis; Acute and subacute bursitis; Epicondylitis; Synovitis of osteoarthritis; Acute gouty arthritis; Acute nonspecific tenosynovitis; Post-traumatic osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). 3. COLLAGEN DISEASE: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus; Systemic dermatomyositis (polymyositis); Acute rheumatic carditis. 4. DERMATOLOGICAL DISEASES: Bullous dermatitis herpetiformis; Pemphigus; Severe psoriasis; Severe seborrhoeic dermatitis; Exfoliative dermatitis; Mycosis fungoides; Severe erythema multiforme (Stevens-Johnson Syndrome). 5. ALLERGIC STATES: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma; Drug hypersensitivity reactions; Contact dermatitis; Urticarial transfusion reactions; Atopic dermatitis; Serum sickness; Seasonal or perennial allergic rhinitis; Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice). 6. OPHTHALMIC DISEASES: Severe acute and chronic allergic and inflammatory processes involving the eye, such as : Allergic corneal marginal ulcers; Allergic conjunctivitis; Chorioretinitis; Anterior segment inflammation; Herpes zoster ophthalmicus; Iritis, iridocyclitis; Diffuse posterior uveitis and choroiditis; Keratitis; Optic neuritis; Sympathetic ophthalmia. 7. GASTROINTESTINAL DISEASES: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy); Regional enteritis (systemic therapy). 8. RESPIRATORY DISEASES: Symptomatic sarcoidosis; Berylliosis; Aspiration pneumonitis; Loeffler's syndrome not manageable by other means; Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. 9. HAEMATOLOGIC DISORDERS: Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated); Secondary thrombocytopenia in adults; Acquired (autoimmune) haemolytic anaemia; Erythroblastopenia (RBC anaemia); Congenital (erythroid) hypoplastic anaemia. 10. NEOPLASTIC DISEASES: For palliative management of: Leukaemias and lymphomas in adults; Acute leukaemia of childhood. 11. OEDEMATOUS STATES: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. 12. NERVOUS SYSTEM: Acute exacerbations of multiple sclerosis. 13. MISCELLANEOUS: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.Trichinosis with neurologi c or myocardial involvement. SOLU-MEDROL is beneficial as adjunctive therapy in the treatment of AIDS patients with moderate to severe Pneumocystis carinii pneumonia (PCP) when given within the first 72 hours of initial anti-pneumocystis treatment.

Table of characteristics
Table of characteristics
Active ingredient
Medicine schedule
1 vial of powder - 500mg: Prescription Only Medicine, or Prescription Animal Remedy
1 vial of diluent - 8mL: Not scheduled. Not considered by committee
Part 1
Part 1
Visual appearance White freeze dried cake and diluent in separate vial.
Dosage Form Injection, powder for
Route of administration Intravenous
Part 2
Part 2
Visual appearance Clear colourless liquid
Dosage Form Diluent, not applicable
Route of administration Intravenous

There is one type of pack available.

We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo
Feedback